eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
vol. 35
Letter to the Editor

Acute urticaria: an extremely rare adverse effect of levonorgestrel-releasing intrauterine system as a possible manifestation of progestogen hypersensitivity syndrome

Justyna Emeryk-Maksymiuk, Anna Grzywa-Celińska, Sławomir Woźniak, Piotr Szkodziak, Michał Szczyrek

Adv Dermatol Allergol 2018; XXXV (5): 530–531
Online publish date: 2018/07/19
View full text
Get citation
JabRef, Mendeley
Papers, Reference Manager, RefWorks, Zotero
A 34-year-old Caucasian woman underwent insertion of a levonorgestrel-releasing intrauterine system (Mirena®) for contraception in March 2016. The patient was in good general health and was menstruating regularly. The routine gynecological examination before the insertion of Mirena® was normal. Cytology and ultrasound examinations of the reproductive organs were also normal. The patient had a history of allergic rhinoconjunctivitis to birch, alder and hazel pollens. Before the insertion of Mirena® she was taking oral antihistamine and nasal glucocorticosteroid in typical doses for about 10 days to relieve the symptoms of allergic rhinoconjunctivitis as it was the pollen season of alder and hazel. On the implantation day, the patient did not drink alcohol and avoided strenuous exercises.
Mirena® was inserted according to the manufacturer’s instructions without any complications. Two hours after the procedure, the patient felt slightly dizzy and developed erythematous skin rash on her thighs, abdomen, chest and buttocks. Within the next 2 h, typical wheals occurred on the abdomen (Figure 1) and she developed pruritus of the feet. Her general condition was good, vital signs were normal; there were no respiratory or gastrointestinal symptoms.
The patient’s condition was diagnosed by an allergologist as “acute urticaria probably caused by an allergic reaction”. She was advised to remove Mirena® as fast as possible and to take 20 mg of oral methylprednisolone and 180 mg of fexofenadine for 5 days. On the same day in the evening, Mirena® was removed. The gynecological examination did not reveal any skin rash, or mucosal congestion or edema of the urogenital region. The removed device showed no visible evidence of damage. The next day, the patient’s skin condition improved; urticaria resolved completely two days after the removal of Mirena® and treatment with aforementioned medications. Urticaria did not recur.
The levonorgestrel-releasing intrauterine system is a long-term, highly effective, safe and reversible method of contraception [1, 2]. According to the manufacturer’s information, the skin rash or/and urticaria are classified as rare (≥ 1/10000 to < 1/1000) adverse events observed during the use of Mirena® [3]. Cox et al. [4] in their study, which involved the population of 678 women with the device, report that its removal before the 5-year period of use was required in 92 cases, yet only in one case its removal was...

View full text...
Mansour D. The benefits and risks of using a levonorgestrel-releasing intrauterine system for contraception. Contraception 2012; 85: 224-34.
Hardeman J, Weiss BD. Intrauterine devices: an update. Am Fam Physician 2014; 89: 445-50.
Mirena – product information. Available at: http://www.bayerresources.com.au/resources/uploads/PI/file9399.pdf
Cox M, Tripp J, Blacksell S. Clinical performance of the levonogestrel intrauterine system in routine use by the UK Family Planning and Reproductive Health Research Network: 5-year report. J Fam Plann Reprod Health Care 2002; 28: 73-7.
Chen X, Wu X, Zhu H. Acute urticaria as a side effect of the Mirena® (levonorgestrel-releasing intrauterine system): a case report. BMC Res Notes 2014; 7: 209.
Pereira A, Coker A. Hypersensitivity to Mirena – a rare complication. J Obstet Gynaecol 2003; 23: 81.
Foer D, Buchkeit KM, Gargiulo AR, et al. Progesteron hypersensitivity in 24 cases: diagnosis, management and proposed renaming and classification. J Allergy Clin Immunol Pract 2016; 4: 723-9.
Cristaudo A, Bordignon V, Palamara F, et al. Progesterone sensitive interferon-gamma producing cells detected by ELISpot assay in autoimmune progesterone dermatitis. Clin Exp Dermatol 2007; 32: 439-41.
Nguyen T, Razzague A. Autoimmune progesterone dermatitis: update and insights. Autoimmun Rev 2016; 15: 191-7.
Shahar E, Bergman R, Pollack S. Autoimmune progesterone dermatitis: effective prophylactic treatment with danazol. Int J Dermatol 1997; 36: 708-11.
Fournier JB. Resolution of autoimmune progesterone dermatitis after treatment with oral contraceptives. JAAD Case Rep 2015; 25: 319-20.
Medeiros S, Rodrigues-Alves R, Costa M, et al. Autoimmune progesterone dermatitis: treatment with oophorectomy. Clin Exp Dermatol 2010; 35: 12-3.
Jakubovic BD, Saperia C, Sussman GL. Anaphylaxis following a transvaginal ultrasound. Allergy Asthma Clin Immunol 2016; 12: 3.
Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe